Atul Kothari1, Mary J Burgess2, Juan Carlos Rico Crescencio2, Joshua L Kennedy3, Jesse L Denson4, Kurt C Schwalm5, Ashley N Stoner6, John C Kincaid7, Faith E Davies8, Darrell L Dinwiddie9. 1. Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: akothari@uams.edu. 2. Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 3. Division of Allergy and Immunology, Department of Medicine and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 4. Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM, USA. 5. Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. 6. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 7. Arkansas Children's Hospital, Little Rock, AR, USA. 8. Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 9. Clinical Translational Sciences Center, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Abstract
BACKGROUND: Respiratory viral infections are a significant problem in patients with hematologic malignancies. We report a cluster of HPIV 3 infections in our myeloma patients, and describe the utility of next generation sequencing (NGS) to identify transmission linkages which can assist in infection prevention. OBJECTIVES: To evaluate the utility of NGS to track respiratory viral infection outbreaks and delineate between community acquired and nosocomial infections in our cancer units. STUDY DESIGN: Retrospective chart review conducted at a single site. All patients diagnosed with multiple myeloma who developed symptoms suggestive of upper respiratory tract infection (URTI) or lower respiratory tract infection (LRTI) along with a respiratory viral panel (RVP) test positive for HPIV 3 between April 1, 2016, to June 30, 2016, were included. Sequencing was performed on the Illumina MiSeq™. To gain understanding regarding community strains of HPIV 3 during the same season, we also performed NGS on HPIV3 strains isolated from pediatric cases. RESULTS: We saw a cluster of 13 cases of HPIV3 infections in the myeloma unit. Using standard epidemiologic criteria, 3 cases were considered community acquired, 7 cases developed infection during treatment in the cancer infusion center, while an additional 3 developed infections during hospital stay. Seven patients required hospitalization for a median duration of 20days. NGS enabled sensitive discrimination of the relatedness of the isolates obtained during the outbreak and provided evidence for source of transmission. Two hospital onset infections could be tracked to an index case; the genome sequences of HPIV 3 strains from these 3 patients only differed by a single nucleotide. CONCLUSIONS: NGS offers a significantly higher discriminatory value as an epidemiologic tool, and can be used to gather real-time information and identification of transmission linkages to assist in infection prevention in immunocompromised patients.
BACKGROUND:Respiratory viral infections are a significant problem in patients with hematologic malignancies. We report a cluster of HPIV 3infections in our myelomapatients, and describe the utility of next generation sequencing (NGS) to identify transmission linkages which can assist in infection prevention. OBJECTIVES: To evaluate the utility of NGS to track respiratory viral infection outbreaks and delineate between community acquired and nosocomial infections in our cancer units. STUDY DESIGN: Retrospective chart review conducted at a single site. All patients diagnosed with multiple myeloma who developed symptoms suggestive of upper respiratory tract infection (URTI) or lower respiratory tract infection (LRTI) along with a respiratory viral panel (RVP) test positive for HPIV 3 between April 1, 2016, to June 30, 2016, were included. Sequencing was performed on the Illumina MiSeq™. To gain understanding regarding community strains of HPIV 3 during the same season, we also performed NGS on HPIV3 strains isolated from pediatric cases. RESULTS: We saw a cluster of 13 cases of HPIV3 infections in the myeloma unit. Using standard epidemiologic criteria, 3 cases were considered community acquired, 7 cases developed infection during treatment in the cancer infusion center, while an additional 3 developed infections during hospital stay. Seven patients required hospitalization for a median duration of 20days. NGS enabled sensitive discrimination of the relatedness of the isolates obtained during the outbreak and provided evidence for source of transmission. Two hospital onset infections could be tracked to an index case; the genome sequences of HPIV 3 strains from these 3 patients only differed by a single nucleotide. CONCLUSIONS: NGS offers a significantly higher discriminatory value as an epidemiologic tool, and can be used to gather real-time information and identification of transmission linkages to assist in infection prevention in immunocompromised patients.
Authors: Celalettin Ustun; Jiří Slabý; Ryan M Shanley; Jan Vydra; Angela R Smith; John E Wagner; Daniel J Weisdorf; Jo-Anne H Young Journal: Biol Blood Marrow Transplant Date: 2012-04-21 Impact factor: 5.742
Authors: Rodrigo Martino; Rocío Parody Porras; Nuria Rabella; John V Williams; Elena Rámila; Nuria Margall; Rosa Labeaga; James E Crowe; Pedro Coll; Jorge Sierra Journal: Biol Blood Marrow Transplant Date: 2005-10 Impact factor: 5.742
Authors: Hamid Jalal; David F Bibby; Julie Bennett; Rebecca E Sampson; Nicola S Brink; Stephen MacKinnon; Richard S Tedder; Katherine N Ward Journal: J Clin Microbiol Date: 2007-03-28 Impact factor: 5.948
Authors: W Garrett Nichols; Dean D Erdman; Alison Han; Carol Zukerman; Lawrence Corey; Michael Boeckh Journal: Biol Blood Marrow Transplant Date: 2004-01 Impact factor: 5.742
Authors: Helen Y Chu; Janet A Englund; Sara Podczervinski; Jane Kuypers; Angela P Campbell; Michael Boeckh; Steven A Pergam; Corey Casper Journal: Biol Blood Marrow Transplant Date: 2014-03-06 Impact factor: 5.742
Authors: Anthony D Sung; Julia A M Sung; Samantha Thomas; Terry Hyslop; Cristina Gasparetto; Gwynn Long; David Rizzieri; Keith M Sullivan; Kelly Corbet; Gloria Broadwater; Nelson J Chao; Mitchell E Horwitz Journal: Clin Infect Dis Date: 2016-08-01 Impact factor: 9.079
Authors: Alexander L Greninger; Danielle M Zerr; Xuan Qin; Amanda L Adler; Reigran Sampoleo; Jane M Kuypers; Janet A Englund; Keith R Jerome Journal: J Clin Microbiol Date: 2016-12-28 Impact factor: 5.948
Authors: Justin Lessler; Nicholas G Reich; Ron Brookmeyer; Trish M Perl; Kenrad E Nelson; Derek A T Cummings Journal: Lancet Infect Dis Date: 2009-05 Impact factor: 25.071
Authors: Kristine M Wylie; Todd N Wylie; Richard Buller; Brandi Herter; Maria T Cannella; Gregory A Storch Journal: J Clin Microbiol Date: 2018-11-27 Impact factor: 5.948
Authors: Darrell L Dinwiddie; Olga Hardin; Jesse L Denson; John C Kincaid; Kurt C Schwalm; Ashley N Stoner; Thomas J Abramo; Tonya M Thompson; Claire M Putt; Stephen A Young; Walter N Dehority; Joshua L Kennedy Journal: Genome Announc Date: 2018-05-24
Authors: Amanda M Casto; Amanda L Adler; Negar Makhsous; Kristen Crawford; Xuan Qin; Jane M Kuypers; Meei-Li Huang; Danielle M Zerr; Alexander L Greninger Journal: Clin Infect Dis Date: 2019-08-30 Impact factor: 9.079
Authors: Julia Tabatabai; Paul Schnitzler; Christiane Prifert; Martin Schiller; Benedikt Weissbrich; Marie von Lilienfeld-Toal; Daniel Teschner; Karin Jordan; Carsten Müller-Tidow; Gerlinde Egerer; Nicola Giesen Journal: PLoS One Date: 2022-07-29 Impact factor: 3.752